Discover
SLS
SELLAS Life Sciences Group, Inc.
9.68
2 x 6.92
2 x 12.00
bid
ask
-
0.47
4.68%
2 @ 07:59 PM
9.67 -0.01 (0.11%)
| Ytd | 156.76% | |
| 1y | 406.81% |
9.30
day range
9.79
1.39
52 week range
15.88
| Open | 9.63 | Prev Close | 10.15 | Low | 9.30 | High | 9.79 | Mkt Cap | 1.95B |
| Vol | 6.26M | Avg Vol | 6.65M | EPS | -0.21 | P/E | N/A | Forward P/E | -93.40 |
| Beta | 2.57 | Short Ratio | 10.31 | Inst. Own | 36.98% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 12.23 | 200-d Avg | 8.54 | 1yr Est | 32.50 |
| Income Statement | |||
| Operating Expenses | 10.63M | ||
| Research and Development Expense | 6.27M | ||
| Selling, General and Administrative Expense | 4.36M | ||
| Operating Income | -10.63M | ||
| Net Income | -9.60M | ||
| Net Income Common Stock | -9.60M | ||
| Net Income Common Stock (USD) | -9.60M | ||
| Consolidated Income | -9.60M | ||
| Earnings per Basic Share | -0.05 | ||
| Earnings per Basic Share (USD) | -0.05 | ||
| Earnings per Diluted Share | -0.05 | ||
| Earning Before Interest & Taxes (EBIT) | -9.60M | ||
| Earning Before Interest & Taxes (USD) | -9.60M | ||
| Weighted Average Shares | 189.18M | ||
| Weighted Average Shares Diluted | 189.18M | ||
| Balance Sheet | |||
| Cash and Equivalents | 138.44M | ||
| Cash and Equivalents (USD) | 138.44M | ||
| Current Assets | 142.51M | ||
| Property, Plant & Equipment Net | 710.00K | ||
| Total Assets | 145.38M | ||
| Debt Current | 580.00K | ||
| Total Debt | 737.00K | ||
| Current Liabilities | 7.57M | ||
| Debt Non-Current | 157.00K | ||
| Total Liabilities | 7.73M | ||
| Accumulated Retained Earnings (Deficit) | -293.00M | ||
| Shareholders Equity | 137.66M | ||
| Shareholders Equity (USD) | 137.66M | ||
| Assets Non-Current | 2.88M | ||
| Total Debt (USD) | 737.00K | ||
| Goodwill and Intangible Assets | 1.91M | ||
| Liabilities Non-Current | 157.00K | ||
| Trade and Non-Trade Payables | 3.09M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 154.00K | ||
| Net Cash Flow from Financing | 38.83M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 31.25M | ||
| Issuance (Purchase) of Equity Shares | 38.83M | ||
| Net Cash Flow from Operations | -7.59M | ||
| Share Based Compensation | 1.01M | ||